Evaluation of Tropaeolin 000-1 as a Colorimetric Reagent for Assay of Duloxetine and Escitalopram in Solid Dosage Form by Ganesh, Mani et al.
Ganesh et al 
Trop J Pharm Res, March 2016; 15(3): 613  
 
Tropical Journal of Pharmaceutical Research March 2016; 15 (3): 613-621 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v15i3.25 
Original Research Article 
 
 
Evaluation of Tropaeolin 000-1 as a Colorimetric Reagent 
for Assay of Duloxetine and Escitalopram in Solid Dosage 
Form 
 
Mani Ganesh1,2, Abidov Sh Aziz1, Mei Mei Peng1, Ramaswamy Ravikumar1, 
Kalaimani Sakthimanigandan2, Seung Eun Cha3,4 and Hyun Tae Jang1* 
1Department of Chemical Engineering, Hanseo University, 360 Daegok-ri, Haemi-myun, Seosan-si 356 706, 
Chungcheongnam-do, South Korea, 2Alkem Lab ltd,C-17/7,MIDC Industrial Area,Taloja-410208,Raigad District, Navi Mumbai, 
Maharashtra, India, 3Hanseo Regional Innovation Center, Hanseo University, Chungcheongnam-Do, 4Department of Business 
Administration, Sungkyunkwan University, Seoul, South Korea 
 
*For correspondence: Email: htjang@hanseo.ac.kr, chemgans@gmail.com; Tel: +82-41-660-1423; Fax: +82-41-688- 
 
Received: 15 July 2015        Revised accepted: 28 January 2016 
 
Abstract 
Purpose: To explore the application of tropaeolin 000-1 reagent for the rapid, precise and accurate 
determination of duloxetine hydrochloride (DX) and escitalopram maleate (ECT).  
Methods: Determination of DX and ECT was based on the formation of complexes between the dye, 
DX and ECT in 0.1 M HCl. The resulting chromogen showed a maximum wavelength of absorption at 
502 and 503 nm for DX and ECT, respectively. This method was validated for analytical parameters 
such as linearity, precision, accuracy, robustness, and ruggedness according to the guidelines of 
International Conference on Harmonization (ICH) and United States Pharmacopoeia (USP). 
Results: The absorbance of the each chromogen formed with DX and ECT was linear over the range of 
4 - 30 and 2.5 - 27.5 µg mL-1 for DX and ECT, with 0.9968 and 0.9979 as the regression coefficient, 
respectively. The limits of detection (LOD) were 0.0045 and 0.0015 μg mL-1 for DX and ECT, 
respectively, with the limits of quantification (LOQ) at 0.5 and 0.08 μg mL-1. The recovery (accuracy) of 
the methods resulted in low RSD values of 0.856 – 0.983 % for DX and 0.765 – 0.987 % for ECT. 
Conclusion: The developed method shows a high degree of accuracy and precision for the 
determination of DX and ECT. Thus, tropaeolin 000-1 reagent is versatile for determining the contents 
of DX and ECT in their formulations.  
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Acid dyes such as methyl orange and 
bromocresol green are ideal reagents for the 
extractive colorimetric determination of various 
nitrogen-containing pharmaceuticals. The 
maximum wavelength that can be used to 
examine such drugs with methyl orange and 
bromocresol green ranges from 410 to 415 nm, 
and these compounds experience interference 
with material that have UV absorption, such as 
certain preservatives and diluents present in 
solid dosage forms. Other commonly used 
colorimetric reagents require specific functional 
groups such as primary amine, phenolic, and 
aldehydic groups, which makes methods that use 
them more laborious than extractive colorimetric 
procedures [1-4].  
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Tropaeolin 000-1 (TO), or α-naphthol orange, 
has been identified as a useful extractive 
colorimetric reagent for the estimation of 
pharmaceuticals [5]. The sulfonic acid group of 
TO that forms in the presence of acid can 
combine with pharmaceuticals containing basic 
nitrogen (positively charged groups). A plausible 
mechanism for the formation of color is provided 
in Fig 1. This is the first step in the ionization of 
the dye, as well as the positively charged drug, in 
the presence of acid or buffer media. The 
molecules then combine to form a single species 
of colored chromogen. In this study, we selected 
DX and ECT to examine the versatility of TO in 
estimating drugs in their dosage forms. 
 
Duloxetine hydrochloride (DX) has the chemical 
formula (+)-(S)-N-methyl-3-(1-naphthalenyloxy)-
2-thiophene propanamine hydrochloride. It is a 
selective serotonin and nor-epinephrine re-
uptake inhibitor that was recently approved by 
the United States FDA. This compound can be 
used for the treatment of major depressive 
disorders (MDD) and diabetic peripheral 
neuropathic pain [6,7]. Previous studies on 
analytical methods for DX estimated its 
concentration using chromatographic, UV 
spectrophotometric, or colorimetric methods [8-
14].  
 
The second drug examined, escitalopram oxalate 
(ECT), has the chemical formula S (+)-1-[3-
(dimethyl-amino) propyl]-1-(p-fluorophenyl)-5-
phthalancarbonitrile, and is a highly active S (+) 
enantiomer of citalopram. It is also an orally 
administered selective serotonin reuptake 
inhibitor (SSRI) prescribed for depression, panic, 
premenstrual dysphoric, and obsessive-
compulsive disorder [15,16]. Methods such as 
chromatographic, spectrophotometric, 
colorimetric, and extractive colorimetric 
estimation using bromocresol green and methyl 
orange have been used in pharmaceutical and 
biological matrices [17-20]. 
 
Extractive colorimetric procedures are popular 
because of their sensitivity and selectivity toward 
the active component of interest. Due to the ease 
of these methods, they can be used for the 
quantitative determination of many 
pharmaceuticals. Up to now, there have been no 
reports on the estimation of duloxetine HCl and 
escitalopram oxalate using TO as an ion-pairing 
agent. In the present study, we report a simple, 
accurate, and precise extractive colorimetric 
method for the estimation of DX and ECT; its 
suitability was validated for assaying DX and 





Standard duloxetine HCl (DX) and escitalopram 
oxalate (ECT) were obtained from Sigma Aldrich 
GmbH (Germany), tropaeolin 000-1 was 
purchased from TCI Chemicals (Japan), and 
methyl orange, chloroform, and other chemicals 





Shimadzu UVmini-1240 UV-Visible 
spectrophotometer and Scinco Neosys-2000 
DRS-UV systems were used with 1-cm quartz 
cells for spectral measurements along with 
Shimadzu UV Probe software (version 2.1).  
 
Preparation of drug stock solutions  
 
Stock solutions of 1 mg mL-1 of standard drugs 
were prepared by dissolving 100 mg of DX or 
ECT in 100 mL of water using volumetric flasks. 
Working standards were prepared by suitably 




Aliquots of secondary stocks were transferred 
into a series of 50-mL separating funnels, after 
which 2 mL of aqueous solution of 0.2 % (w/v) 
TO reagent were added. The mixtures were 
shaken well, and 6 mL of 0.1 M HCl was added 
and mixed. The orange-red chromogen that 
formed was extracted using 10 mL of chloroform. 
To absorb the water present in the organic layer, 
it was passed through dried anhydrous sodium 
sulfate (2 g) in a cotton-plugged funnel. 
 
Absorbance and linearity determination  
 
Full-scan absorption spectra of both colored ion-
pair complexes were acquired by scanning the 
chloroform layer of the chromogen from 370 to 
800 nm against a reagent blank prepared by the 
same procedure by omitting the drug.  
 
Analytical method optimization 
 
Several experiments were performed to optimize 
conditions and obtain quantitative orange-red 
ion-pair complexes. Method validation was 
performed based on USP [21] and ICH [22] 
guidelines. The optimization experiments 
revealed that the reproducible formation of the 
orange-red ion pair required 6 mL of 0.1 M HCl. 
Various solvents were tested for extraction; 
chloroform was found to perform best. The same 
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conditions are recommended for the extractive 
colorimetric estimations of other pharmaceuticals 
[13,14,20].  
 
LOD and LOQ of the method 
 
The lowest possible quantity of drug detectable 
by the developed procedure is called the limit of 
detection (LOD), and the lowest possible quantity 
of the drug that can be used in the estimation or 
assay of the drug is called the limit of quantitation 
(LOQ). These levels were established as in Eq 1. 
 
LOD or LOQ = ĸ SD a/b …………………….. (1) 
 
where ĸ = 3 for LOD and 10 for LOQ, SD is the 
standard deviation of the intercept (a), and b is 




The precision of the method was estimated by 
examining the intra-day and inter-day precision, 
both of which express the closeness of 
agreement between a series of results or 
measurements under specified conditions. Six-
fold replicate analyses on each sample were 
used to examine method repeatability. Intra-day 
precision was performed on the same day at 
different time intervals. Inter-day precision was 
established based on the results of the same 




Accuracy is the degree of agreement between 
the results determined by the method and the 
true value. A standard spiking procedure was 
followed to determine the accuracy by spiking a 
known quantity of standard into the pre-analyzed 
assay sample, and estimation of the results was 
performed using the method. 
 
Assay of formulations 
 
Twenty tablets of each drug were weighed 
separately and then ground to fine powder 
separately, and the average tablet weight was 
calculated. A quantity of powder required for 
specific dilution of the particular drug was 
accurately weighed and transferred into a 50-ml 
volumetric flask. A small amount of water was 
added and the mixture was sonicated for 5 min to 
dissolve the drug, after which the final volume 
was created by adding water up to the mark. The 
final solution was filtered to remove insoluble 
excipients using a 0.45-µm membrane filter. 
 
Study of placebo interference with the 
proposed method 
 
It is necessary to evaluate the effect of the 
placebo during analytical method validation since 
excipients present in the formulation may 
interfere with estimation of the drug. To study 
this, common excipients such as magnesium 
stearate, talc, and lactose were examined. A 
defined quantity of each of the above excipients 
was mixed with 60 mg of DX and ECT, and the 
method was followed. The percentage recovery 
of the drug from the excipients was calculated 
[21]. 
 
Bench-top stability of chromogen 
 
Stability is an important parameter for 
colorimetric procedures. To study the stability of 
the color formed by the ion pairs, a specified 
quantity of stock was mixed with constant 
quantities of TO and HCl, the mixtures were held 
for varying times to complete the reaction, and 
the mixtures were extracted with chloroform. The 
absorbance of chromogen was measured at 
various time intervals and plotted as a graph of 
time vs. absorbance. 
 
Robustness and ruggedness 
 
To study the effects of deliberate changes in the 
method, defined as the robustness of the 
method, changes in the wavelength of estimation 
and the quantity of the dyes were considered. 
Likewise, inter-analyst and inter-instrument 
variations were analyzed to study ruggedness. 
Ruggedness was documented by determining 
the drug in the marketed formulation using two 
different spectrophotometers, a Shimadzu 
UVmini-1240 (system I) and a Scinco Neosys-
2000 DRS-UV with liquid sample analysis ports 
(system II), and two different analysts. 
 
Effect of TO concentration and quantity 
 
To validate the effect of TO concentration on the 
effective formation of chromogen, we measured 
the absorbance of solutions containing fixed 
concentrations of DX and ECT with 0.5 mL of 
solutions with various concentrations (0.10 – 




Origin 8 statistical and graphical software was 
used for deriving regression equations and 
linearity curves. Microsoft Excel 2007 software 
was also used to calculate means and standard 
deviations. Student’s t-tests and F-tests were 
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performed using SPSS version 10.0 (SPSS inc, 




Upon hydrolysis, TO became anionic and formed 
a bright orange-red complex (charge transfer 
complex) with the cationic nitrogen present in DX 
and ECT.  
 
After formation of the ion-pair complex, the dye 
and drug act as a single molecule and the force 
stabilizing this single unit is electrostatic in 




Full-scan absorption spectra are illustrated in Fig 
2(a). Based on the figure, the maximum 
absorbance wavelengths (λmax) for DX-TO and 
ECT-TO are 502 and 503 nm for DX and ECT, 
respectively. Each λmax was used for further 
studies on the estimation of DX and ECT in bulk 







Linearity and range 
 
The Beer’s law limit, molar absorptivity, and λmax 
were determined, and the results are provided in 
Fig. 2(b) and Table 1. To determine the Beer’s 
law limit, a calibration curve was constructed by 
plotting absorbance against concentration (Fig 
2(b)), and regression was calculated using Eq 2. 
 
A = bX - C ………………………………. (2) 
 
where A is the absorbance of the chromogen 
formed with DX or ECT, X is the drug 
concentration in μg mL-1, and r is the correlation 
coefficient. Other optical parameters such as 
molar absorptivity (Є) and Sandell’s sensitivity 
were also determined and are presented in Table 
1.  
 
LOD and LOQ  
 
The LODs of DX and ECT were determined as 
0.0045 and 0.0015 μg mL-1, respectively, and the 
LOQs for DX and ECT were found to be 0.5 and 




  Figure 1: Plausible mechanism for formation of an ion pair between TO and drug 
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Table 1: Optical properties of DX and ECT ion pairs with TO 
 
Parameter  DX ion pair ECT ion pair 
λmax 502 nm 503 
Beer’s law limit(μg mL-1) 4-30 2.5-27.5 
Sandell’s sensitivity (μg cm-2/0.001 abs unit) 0.0398 0.04 
Molar absorptivity (Є)  (lit mol cm-1) 1.195 x 104 1.035 x 104 
Regression equation A = bx+c A = bx+c 
Slope (a) 0.029 0.032 
Intercept (b) -0.099 -0.065 
Standard error on slope 0.0006 0.0006 
Standard error on intercept 0.0128 0.0114 
Correlation coefficient (r)  0.997 0.998 
  































Figure 2: (a) Full-scan absorption spectra of complexes of TO with DX or ECT. (b) Beer’s law linear plot of the 
complexes 
 
Assay of the drugs in their formulations 
 
Mean recoveries were 99.8 ± 0.87 and 99.55 ± 
0.75 % for bulk DX and ECT, respectively, 
relative to the label claim. For use of the 
proposed method with the drugs in their 
formulations, market-procured tablets were 
subjected to analysis for their contents of DX and 
ECT based on the proposed method and 
previously reported methods [13,20]. The assay 
results for the marketed formulation of DX and 
ECT by the proposed and reported extractive 
colorimetric methods were found to be 99.77 % 
(99.87 % based on the reported method) and 
99.68 % (99.9 % based on the reported method) 
for DX and ECT, respectively, relative to the label 
claim for each tablet. These results were 
compared using statistical analyses with the 
Student’s t-test and F-test. No significant 
differences were observed between the 
calculated and theoretical values using the 
Student’s t-tests and F-tests at the 95 % 
confidence level, suggesting that the present 
method is comparable with the reference 
methods (Table 2). 
 
Method precision  
 
Method precision results are provided in Table 3. 
The percentage relative standard deviations (% 
 
 





Amount (%) % RSDa Confidence 
Proposed Reported Proposed Reported t-test F-test 
DX  60 99.77±0.53 99.87±0.13 0.66 0.98 0.247 1.089 
ECT  20 99.68±0.41 99.90±0.79 0.56 0.81 0.239 1.045 
  aMean of 6 determinations; btheoretical values at 95% confidence limits for the Student’s t-test and the F-test 
were 2.57 and 5.05, respectively 
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RSD) for inter-day precision were low, at about 
0.878 and 0.975 for DX and ECT, respectively. 
Likewise, the intraday precision % RSD values 
were 0.978 and 0.997 for DX and ECT, 
respectively. These results are suggestive of 




The results of recovery studies are provided in 
Table 3. The mean % RSD for determinations at 
three levels were 0.856 – 0.983% and 0.765 – 
0.987% for DX and ECT, respectively. These 
were within the acceptance limit for accuracy 
based on standard guidelines for analytical 
method validation (< 2 % RSD). 
 
Effect of TO concentration and quantity 
 
Results of range studies are depicted in Fig. 3 
(a). The figure shows that 0.5 mL of 0.2 % w/v 
TO provides a satisfactory maximum absorbance 
with both drugs; hence, the same concentration 
was chosen as a suitable concentration for 
optimal ion-paring. To study the effect of TO 
quantity on the intensity of the chromogen 
formed, various amounts of TO (1 – 3 mL) were 
mixed with the standard drug solutions described 
above. As shown in Fig. 3(b), 2 mL of 0.2 % w/v 
TO was sufficient to form a complex with 
maximum absorbance at the particular 
wavelength of estimation. 
 
Placebo interference  
 
The effects of placebo interference testing are 
presented in Table 4. None of tthe excipients 
studied were found to interfere in the estimation 
of either drug. Likewise, a placebo mixture of the 
excipients did not result in any color in the extract 
in the present method. 
 
Effect of 0.1 M HCl quantity 
 
To explore the effect of the quantity of HCl on the 
intensity of the resulting chromo, various 
amounts of 0.1 M HCl (3 – 9 mL) were mixed 
with the above optimized concentration of dye 
into drug solution, and the intensity of chromogen 
formed was analyzed (Fig. 4(a)). We found that 
about 6 ml of HCl, as stated previously, provided 
a satisfactory chromogen intensity. 
 










% RSDa Amt. found 
(μg mL-1) a 
% RSDa Amt. found 





19.95   ±0.985 
 





75 100.01 0.983 
100 98.96 0.951 











75 99.75 0.987 
100 98.96 0.765 
125 99.64 0.864 
a Mean of 6 determinations 
 









































 Figure 3(a): Effect of TO concentration on ion-pair (b) Effect of TO quantity on ion-pair 
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DX recovery (%) 
(±SD)b 
ECT recovery (%) 
(±SD)b 
Magnesium stearate 99.98±0.891 99.98±0.891 
Talc 99.15±0.451 99.15±0.451 
Lactose 99.07±0.645 99.07±0.645 




Figure 4: (a) Effect of 0.1 M HCl on ion-pair’s color and (b) stability of chromogens 
 
Table 5: Robustness and ruggedness results 
 
Variable %RSD* %RSD* 
Wavelength (nm) 
502 0.452 0.524 
504 0.622 0.912 
TO quantity (ml)   
1.9 0.585 0.754 
2.1 0.665 0.478 
Ruggedness  
Analyst   
I 0.526 0.652 
II 0.683 0.682 
UV system   
I 0.845 0.754 
II 0.683 0.641 
*Mean of 5 determinations 
 
Bench-top stability of chromogen 
 
Plots of color intensity developed by the 
chromogen formed over time were constructed 
for each drug. The plots (Fig. 4(b)) show that the 
chromogens formed are stable for 3.5 h. 
Subsequently, the color intensity decreased. 
 
Robustness and ruggedness 
 
The results obtained for robustness and 
ruggedness (Table 5) are within the 
recommended 2 % RSD for validation 




The azo dye TO is negatively charged because 
of the disassociated sulfonate group [SO3 ], 
which forms an ion complex with positively 
charged drugs with a quaternary nitrogen in their 
structure, such as DX and ECT. These 
oppositely charged TL and TO ions form a stable 
single ion pair of a drug-TO complex by the 
electrostatic force of attraction. 
 
The maximum absorbances of the orange-red 
ion-association complexes of DX and ECT were 
recorded at 502 and 503 nm, respectively. The 
absorbances of the complexes obeyed Beer's 
law over the ranges of 4 – 30 and 2.5 – 27.5 
µg/mL, respectively, for DX and ECT, with 
correlation coefficients of 0.997 and 0.997. The 
percentage recoveries (99.84 – 100.1 and 98.96 
– 99.75 %, respectively, for DX and ECT) and 
method precision values were comparable with 




The proposed extractive ion-pair colorimetric 
estimation method for duloxetine (DX) and 
escitalopram (ECT) in bulk and in their solid 
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dosage form using tropaeolin 000-1 dye as a 
colorimetric reagent is sensitive, specific 
(selective), rapid, and cost-effective. The method 
is specific to the drugs duloxetine and 
escitalopram, as it is free from interference by 
common excipients that are chosen in the study. 
Because the method utilizes simple reagents at 
low concentrations, it is more cost-effective than 
other time-consuming and laborious analytical 
methods. Thus, the method described here is 
suitable for the routine quantitative determination 
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